Quick Answer
Vesugen is the synthetic tripeptide Lys-Glu-Asp (KED), a Khavinson bioregulator associated with vascular tissue. The proposed mechanism is that it reaches the cell nucleus and binds DNA near particular genes, changing how actively they are expressed. The supporting data come mainly from cell cultures and mice, almost all from one research network, and the few human reports are small and not described as placebo-controlled.
Vesugen is one of the more widely studied bioregulators, and its research trail is more varied than its name suggests: it starts with blood vessels and, more recently, ends up in neurons. This article covers what it is, the proposed mechanism, what the studies report in which models, and how much weight the evidence can bear.
What Vesugen is
Vesugen is a tripeptide of lysine, glutamic acid and aspartic acid, written Lys-Glu-Asp or KED (molecular formula C15H26N4O8, molecular weight about 390.4 g/mol). It comes from the bioregulator programme led by Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology. The group describes KED as a vasoprotective peptide found in a polypeptide complex obtained from cattle blood vessels, and the synthetic tripeptide reproduces that proposed active sequence without the extraction step. In some of the group's papers it appears under the laboratory code T-38.
The proposed mechanism
The bioregulator hypothesis holds that peptides of two to four residues can cross the cell and nuclear membranes and bind specific DNA sequences in gene promoter regions, nudging transcription up or down. For Vesugen, a 2014 Russian-language paper used molecular docking, a computer simulation, to propose that KED binds a short sequence in the core promoter of MKI67, the gene for the proliferation marker Ki-67, and reported higher Ki-67 in vascular endothelial cell cultures exposed to the peptide. Later in vitro work reported changes in endothelin-1, connexins and sirtuin-1.
Two caveats matter. Docking predicts where a molecule could bind; it does not show that binding happens inside a living cell, or that it causes the effects observed. And when the group modelled KED and Pinealon against every possible six-base DNA sequence in 2021, it concluded that their binding is probably of low selectivity and stated that the exact mechanism of action is unknown. We also found no indexed study measuring nitric oxide signalling, a mechanism sometimes attributed to Vesugen.
What the studies show
- Vascular cells (cell culture): in ageing organotypic and dissociated cultures of vascular cells, KED (as T-38) raised Ki-67, lowered the apoptosis-associated protein p53 and reduced E-selectin, an adhesion molecule involved in plaque formation. In endothelial cultures modelling atherosclerosis and restenosis, it normalised raised endothelin-1, restored connexin-mediated contact between cells and increased sirtuin-1 expression.
- Other tissues (cell culture): KED stimulated cell proliferation in skin explants from old rats. In human oral stem cells kept to their 25th passage, it lowered mRNA for the senescence markers p16 and p21 by roughly 1.8 to 3.2 fold, in work by an Italian group co-authored with the St Petersburg institute.
- Neurons (cell culture and mice): in mouse hippocampal neurons exposed to amyloid, KED increased mature (mushroom) dendritic spines by 20%. In 5xFAD mice, a model of Alzheimer's disease, it restored the proportion of mushroom spines on hippocampal neurons, with results that differed between males and females. A trend towards restored synaptic plasticity did not reach statistical significance.
- Humans: a small Russian-language study of 32 adults aged 41 to 83 with several chronic conditions reported favourable shifts in biological age markers with Vesugen and Pinealon, but also a pro-oxidant signal and fewer circulating CD34+ blood-forming stem cells. A separate report described improved arterial blood flow measures in 41 patients with atherosclerosis-related arterial insufficiency, compared only before and after treatment.
How strong is the evidence?
Early, and concentrated in one place. Almost every study comes from the St Petersburg institute or groups co-publishing with it, including the papers that reached international journals. A substantial share is published in Russian with only an English abstract available. The animal evidence for the vascular claim itself is thin: the most detailed in vivo study we found is the 2021 mouse work, which concerns neurons rather than blood vessels.
The human data cannot support conclusions. The reports are small, are not described as randomised or placebo-controlled, and no trial of Vesugen is registered on ClinicalTrials.gov. The tissue story is also untidy: KED activity is reported in skin, stem cell and neuronal models as well as vascular cells, which sits awkwardly with strict vascular specificity. A fair summary is a coherent hypothesis with early laboratory support from a single research network, not an established vascular agent.
Where Vesugen fits
Vesugen has often been tested side by side with Pinealon in neuronal models. For how the bioregulators fit together, see our guide to bioregulator peptides and what the Khavinson research actually claims.
References
- Khavinson V, et al. (2021). "Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease." Pharmaceuticals (Basel). PubMed 34071923
- Khavinson VKh, et al. (2014). "Molecular aspects of anti-atherosclerotic effects of short peptides." Bulletin of Experimental Biology and Medicine. PubMed 25408528
- Voicekhovskaya MA, et al. (2012). "Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats." Bulletin of Experimental Biology and Medicine. PubMed 22803085
- Khavinson VKh, et al. (2014). "Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging." Advances in Gerontology (in Russian). PubMed 25051766
- Kozlov KL, et al. (2016). "Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis." Advances in Gerontology (in Russian). PubMed 28539025
- Sinjari B, et al. (2020). "Short Peptides Protect Oral Stem Cells from Ageing." Stem Cell Reviews and Reports. PubMed 31677028
- Kraskovskaya NA, et al. (2017). "Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease." Bulletin of Experimental Biology and Medicine. PubMed 28853087
- Meshchaninov VN, et al. (2015). "Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission." Advances in Gerontology (in Russian). PubMed 26390612
- Kitachev KV, et al. (2014). "The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people." Advances in Gerontology (in Russian). PubMed 25051774